We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

54 hedge funds and large institutions have $204M invested in Karyopharm Therapeutics in 2013 Q4 according to their latest regulatory filings, with 54 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
54
Holders Change
+54
Holders Change %
–
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
54
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.2M
2
PHS
PFM Health Sciences
California
+$16.4M
3
Franklin Resources
Franklin Resources
California
+$14.5M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$9.3M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$8.37M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$53.8M +$43.2M +156,400 New
FCMI
2
Foresite Capital Management I
California
$32.6M +$29.2M +105,716 New
PHS
3
PFM Health Sciences
California
$19.8M +$16.4M +59,301 New
Franklin Resources
4
Franklin Resources
California
$18M +$14.5M +52,460 New
Wellington Management Group
5
Wellington Management Group
Massachusetts
$11.6M +$9.3M +33,681 New
AllianceBernstein
6
AllianceBernstein
Tennessee
$10.4M +$8.37M +30,295 New
BA
7
BlackRock Advisors
Delaware
$7.49M +$6.02M +21,788 New
TG
8
TCW Group
California
$5.53M +$4.44M +16,082 New
BFA
9
BlackRock Fund Advisors
California
$4.89M +$3.93M +14,214 New
BIT
10
BlackRock Institutional Trust
California
$2.83M +$2.28M +8,244 New
Morgan Stanley
11
Morgan Stanley
New York
$2.74M +$2.2M +7,965 New
Principal Financial Group
12
Principal Financial Group
Iowa
$2.54M +$2.04M +7,400 New
State Street
13
State Street
Massachusetts
$2.51M +$2.01M +7,288 New
JP Morgan Chase
14
JP Morgan Chase
New York
$2.49M +$2M +7,239 New
Northern Trust
15
Northern Trust
Illinois
$2.43M +$1.95M +7,064 New
CAM
16
Cormorant Asset Management
Massachusetts
$2.29M +$1.84M +6,667 New
DCM
17
Driehaus Capital Management
Illinois
$2.07M +$1.66M +6,014 New
BG
18
BlackRock Group
United Kingdom
$1.91M +$1.54M +5,560 New
Vanguard Group
19
Vanguard Group
Pennsylvania
$1.79M +$1.44M +5,222 New
Alyeska Investment Group
20
Alyeska Investment Group
Illinois
$1.72M +$1.38M +5,000 New
BBA
21
Baker Bros. Advisors
New York
$1.41M +$1.13M +4,089 New
UBS AM
22
UBS AM
Illinois
$1.07M +$862K +3,120 New
EIM
23
Essex Investment Management
Massachusetts
$890K +$715K +2,587 New
FM
24
Forward Management
California
$822K +$945K +3,422 New
Geode Capital Management
25
Geode Capital Management
Massachusetts
$812K +$653K +2,364 New
1
2 3

KPTI Hedge Fund Activity: Q4 2013 in Review

54 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2013, worth a combined $204M.

Buyers outnumbered sellers: 54 funds opened new KPTI positions and 0 closed out — a net gain of 54 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $43.2M.

  • 54 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2013, up from 0 in Q3 2013.
  • Funds reported $204M of Karyopharm Therapeutics stock for Q4 2013.
  • 54 funds opened new Karyopharm Therapeutics positions in Q4 2013 and 0 closed out, a net change of +54 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2013 was Fidelity Investments, an estimated $43.2M added.

Based on aggregated 13F filings for Q4 2013.